Germany’s Merck KGaA has presented detailed results from cohort B of the global Phase II WILLOW study of enpatoran, an ...

German science and technology firm Merck KGaA (MRK: DE) has moved a step closer to introducing a new therapy for tenosynovial ...

But what does the Cannibal himself think of the situation? He reflects on the current generation of cyclists with his old ...

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants. The U.S. Food ...

Learn more about the effects US pharmaceutical tariffs could have on European companies and their strategies for overcoming ...

In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

At the first ring of the phone, Eddy Merckx, who turns 80 in two days, answers. And, surprisingly, catching off guard, he ...

The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 pati ...

As of 1:13:21 PM GMT+2. Market Open.